GLMD Galmed Pharmaceuticals Ltd.
$4.63▲ +21.05%
Healthcare
Other
Volume 301.2K
Avg Volume (10D) 68.7K
Key Metrics & Fundamentals
Market Cap
$4.95M
P/E Ratio
–
Div Yield
–%
52W Range
3.29 - 13.20
% vs 50 MA
10.05%
% vs 200 MA
174.66%
RSI-14
47.4
MACD Histogram
-0.0900
Beta (1Y vs SPY)
0.61
Free Cash Flow
-$2.13M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.78M
COGS
–
Operating Exp
$2.78M
Operating Income
-$2.78M
EBIT
-$2.78M
Pretax Income
-$2.72M
Net Income
-$2.72M
EPS (Diluted)
-2.86
Price & Volume History
Loading chart…
Recent News
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
PR Newswire · Sep 9, 2026 11:30 AM
Galmed Pharmaceuticals: Q2 Earnings Snapshot
Associated Press · Sep 3, 2026 3:52 PM
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
PR Newswire · Aug 19, 2026 11:00 AM
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
PR Newswire · Aug 17, 2026 1:15 PM
Galmed Pharmaceuticals Develops Oral Film Version of Parkinson's Treatment
MT Newswires · Jul 28, 2026 12:42 PM
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
PR Newswire · Jul 28, 2026 11:00 AM
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
InvestorsHub · Jul 16, 2026 2:05 PM
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
PR Newswire · Jul 16, 2026 11:30 AM
Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal
MT Newswires · Jun 22, 2026 1:55 PM
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
PR Newswire · Jun 22, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GLMD's money flow as a full page
Social Sentiment
No Reddit posts found for GLMD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.